{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T02:00:51Z","timestamp":1776304851590,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Raynaud\u2019s phenomenon (RP) is a vasospastic disorder that affects the small blood vessels in the extremities such as the hands, feet, fingers or toes. It is a debilitating condition that can severely impact the patient\u2019s quality of life. Botulinum toxin (BTX) has been examined as a treatment option for RP, but its effect has been inconclusive. A systematic review has been conducted to determine the current evidence of BTX as a treatment for RP secondary to scleroderma. Major clinical databases Medline, Embase (via Ovid), the Cochrane Central Library, ClinicalTrials.gov, EU Clinical Trials Register and the ISRCTN registry were systematically searched from its inception to 27 November 2023 for studies describing BTX and RP. Standard mean differences of Quick-DASH scores, visual analogue scale pain (VAS-P) score and Raynaud\u2019s condition score (RCS) are reported with BTX treatment with a random-effect model. A total of 890 entries were retrieved. Of these, 19 met the inclusion criteria, and all studies were included for analysis. There was a significant effect (<jats:italic>p<\/jats:italic>\u2009=\u20090.03) with Quick-DASH score and VAS-P score (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001) but a non-significant effect (<jats:italic>p<\/jats:italic>\u2009=\u20090.37) with RCS. BTX is a therapeutic option in the treatment of RP secondary to scleroderma; however, the evidence published so far is not sufficient to credit it as a revolutionary first line treatment. More research is needed to establish dosing, techniques and core outcome measures for BTX in RP.<\/jats:p>","DOI":"10.1007\/s10067-024-07237-3","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T08:28:20Z","timestamp":1732955300000},"page":"81-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A systematic review of botulinum toxin as a treatment for Raynaud\u2019s disease secondary to scleroderma"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-4706","authenticated-orcid":false,"given":"Calver","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Iakovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baptiste","family":"Leurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Langridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"issue":"3","key":"7237_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.rdc.2015.04.005","volume":"41","author":"L Cappelli","year":"2015","unstructured":"Cappelli L, Wigley FM (2015) Management of Raynaud phenomenon and digital ulcers in scleroderma. Rheum Dis Clin 41(3):419\u201338","journal-title":"Rheum Dis Clin"},{"issue":"2","key":"7237_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/2397198319826467","volume":"4","author":"AL Herrick","year":"2019","unstructured":"Herrick AL (2019) Raynaud\u2019s phenomenon. J Scleroderma Relat Disord 4(2):89\u2013101","journal-title":"J Scleroderma Relat Disord"},{"issue":"2","key":"7237_CR3","first-page":"123","volume":"113","author":"KK Temprano","year":"2016","unstructured":"Temprano KK (2016) A review of Raynaud\u2019s disease. Mo Med 113(2):123","journal-title":"Mo Med"},{"issue":"4","key":"7237_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1191\/1358863x05vm639ra","volume":"10","author":"JP Cooke","year":"2005","unstructured":"Cooke JP, Marshall JM (2005) Mechanisms of Raynaud\u2019s disease. Vasc Med 10(4):293\u2013307","journal-title":"Vasc Med"},{"issue":"1","key":"7237_CR5","doi-asserted-by":"publisher","first-page":"101474","DOI":"10.1016\/j.berh.2019.101474","volume":"34","author":"AL Herrick","year":"2020","unstructured":"Herrick AL, Wigley FM (2020) Raynaud\u2019s phenomenon. Best Pract Res: Clin Rheumatol 34(1):101474","journal-title":"Best Pract Res: Clin Rheumatol"},{"key":"7237_CR6","doi-asserted-by":"crossref","unstructured":"Nawaz I, Nawaz Y, Nawaz E, Manan MR, Mahmood A (2022) Raynaud\u2019s phenomenon: reviewing the pathophysiology and management strategies. Cureus 14(1)","DOI":"10.7759\/cureus.21681"},{"key":"7237_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/VHRM.S4551","volume":"6","author":"TL Levien","year":"2010","unstructured":"Levien TL (2010) Advances in the treatment of Raynaud\u2019s phenomenon. Vasc Health Risk Manag 6:167\u2013177","journal-title":"Vasc Health Risk Manag"},{"issue":"10","key":"7237_CR8","first-page":"1911","volume":"40","author":"G Lepri","year":"2022","unstructured":"Lepri G, Orlandi M, Di Battista M, De Mattia G, Da Rio M, Codullo V et al (2022) Systemic sclerosis: one year in review 2022. Clin Exp Rheumatol 40(10):1911\u201320","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"7237_CR9","first-page":"1567","volume":"41","author":"M Di Battista","year":"2023","unstructured":"Di Battista M, Lepri G, Codullo V, Da Rio M, Fiorentini E, Della Rossa A et al (2023) Systemic sclerosis: one year in review 2023. Clin Exp Rheumatol 41(8):1567\u201374","journal-title":"Clin Exp Rheumatol"},{"key":"7237_CR10","unstructured":"Karadag DT, Yalcinkaya Y, Akdogan A, Avanoglu A, Bes C, Birlik AM, et al (2023) Treatment of systemic sclerosis-associated digital ulcers: recommendations of the Turkish Society for Rheumatology. Clin Exp Rheumatol 41(8)"},{"issue":"6","key":"7237_CR11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.jvs.2013.03.012","volume":"57","author":"GJ Landry","year":"2013","unstructured":"Landry GJ (2013) Current medical and surgical management of Raynaud\u2019s syndrome. J Vasc Surg 57(6):1710\u20136","journal-title":"J Vasc Surg"},{"key":"7237_CR12","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.2147\/DDDT.S161113","volume":"12","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Liu Y, Hao Y, Feng Y, Pan L, Liu W et al (2018) The mechanism of botulinum A on Raynaud syndrome. Drug Des Devel Ther 12:1905\u20131915","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"7237_CR13","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 6(7):e1000097","journal-title":"PLoS Medicine."},{"issue":"3","key":"7237_CR14","doi-asserted-by":"publisher","first-page":"e0120884","DOI":"10.1371\/journal.pone.0120884","volume":"10","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zhou L, Liu X, Liu L, Wu Y, Zhao Z et al (2015) The effectiveness of the problem-based learning teaching model for use in introductory Chinese undergraduate medical courses: a systematic review and meta-analysis. PLoS One 10(3):e0120884","journal-title":"PLoS One"},{"issue":"9","key":"7237_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (Minors): development and validation of a new instrument. ANZ J Surg 73(9):712\u20136","journal-title":"ANZ J Surg"},{"issue":"10","key":"7237_CR16","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database System Rev Implement Rep 18(10):2127\u20132133","journal-title":"JBI Database System Rev Implement Rep"},{"issue":"8","key":"7237_CR17","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/art.40123","volume":"69","author":"RJ Bello","year":"2017","unstructured":"Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G et al (2017) The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud\u2019s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol 69(8):1661\u20131669","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"7237_CR18","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s10067-019-04762-4","volume":"38","author":"K Dhaliwal","year":"2019","unstructured":"Dhaliwal K, Griffin MF, Salinas S, Howell K, Denton CP, Butler PEM (2019) Optimisation of botulinum toxin type a treatment for the management of Raynaud\u2019s phenomenon using a dorsal approach: a prospective case series. Clin Rheumatol 38(12):3669\u20133676","journal-title":"Clin Rheumatol"},{"issue":"7","key":"7237_CR19","doi-asserted-by":"publisher","first-page":"e15529","DOI":"10.1111\/dth.15529","volume":"35","author":"W Du","year":"2022","unstructured":"Du W, Zhou M, Zhang C, Sun Q (2022) The efficacy of botulinum toxin A in the treatment of Raynaud\u2019s phenomenon in systemic sclerosis: a randomized self-controlled trial. Dermatol Ther 35(7):e15529","journal-title":"Dermatol Ther"},{"issue":"3","key":"7237_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhsa.2008.11.026","volume":"34","author":"A Fregene","year":"2009","unstructured":"Fregene A, Ditmars D, Siddiqui A (2009) Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud\u2019s phenomenon. J Hand Surg Am 34(3):446\u2013452","journal-title":"J Hand Surg Am"},{"issue":"6","key":"7237_CR21","doi-asserted-by":"publisher","first-page":"513.e1","DOI":"10.1016\/j.jhsa.2020.11.005","volume":"46","author":"SH Goldberg","year":"2021","unstructured":"Goldberg SH, Akoon A, Kirchner HL, Deegan J (2021) The effects of botulinum toxin A on pain in ischemic vasospasm. J Hand Surg 46(6):513.e1-513.e12","journal-title":"J Hand Surg"},{"issue":"6","key":"7237_CR22","doi-asserted-by":"publisher","first-page":"e14182","DOI":"10.1111\/dth.14182","volume":"33","author":"SM Habib","year":"2020","unstructured":"Habib SM, Brenninkmeijer EEA, Vermeer MH, de Vries-Bouwstra JK, Velthuis PJ (2020) Botulinum toxin type A in the treatment of Raynaud\u2019s phenomenon. Dermatol Ther 33(6):e14182","journal-title":"Dermatol Ther"},{"issue":"4","key":"7237_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5152\/eurjrheum.2018.18013","volume":"5","author":"S Medina","year":"2018","unstructured":"Medina S, G\u00f3mez-Zubiaur A, Valdeolivas-Casillas N, Polo-Rodr\u00edguez I, Ru\u00edz L, Izquierdo C et al (2018) Botulinum toxin type A in the treatment of Raynaud\u2019s phenomenon: a three-year follow-up study. Eur J Rheumatol 5(4):224\u2013229","journal-title":"Eur J Rheumatol"},{"issue":"7","key":"7237_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2340\/00015555-2665","volume":"97","author":"SI Motegi","year":"2017","unstructured":"Motegi SI, Uehara A, Yamada K, Sekiguchi A, Fujiwara C, Toki S, Date Y, Nakamura T, Ishikawa O (2017) Efficacy of botulinum toxin B injection for Raynaud\u2019s phenomenon and digital ulcers in patients with systemic sclerosis. Acta Derm Venereol 97(7):843\u2013850","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"7237_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/1346-8138.13030","volume":"43","author":"SI Motegi","year":"2016","unstructured":"Motegi SI, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, Ishikawa O (2016) Beneficial effect of botulinum toxin A on Raynaud\u2019s phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol 43(1):56\u201362","journal-title":"J Dermatol"},{"issue":"5","key":"7237_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00296-020-04606-4","volume":"41","author":"M Nagarajan","year":"2021","unstructured":"Nagarajan M, McArthur P (2021) Targeted high concentration botulinum toxin A injections in patients with Raynaud\u2019s phenomenon: a retrospective single-centre experience. Rheumatol Int 41(5):943\u2013949","journal-title":"Rheumatol Int"},{"issue":"1","key":"7237_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/DSS.0000000000002397","volume":"47","author":"L Quintana Castanedo","year":"2021","unstructured":"Quintana Castanedo L, Feito Rodriguez M, Nieto Rodriguez D, Maseda Pedrero R, Chiloeches Fernandez C, de Lucas LR (2021) Botulinum toxin A treatment for primary and secondary Raynaud\u2019s phenomenon in teenagers. Dermatol Surg 47(1):61\u201364","journal-title":"Dermatol Surg"},{"key":"7237_CR28","doi-asserted-by":"crossref","unstructured":"Senet P, Maillard H, Diot E, Lazareth I, Blaise S, Arnault JP, Pistorius MA, Boulon C, Cogrel O, Warzocha U, Rivi\u00e8re S, Malloizel-Delaunay J, Servettaz A, Sassolas B, Viguier M, Monfort JB, Janique S, Vicaut E, BRASS collaborators (2023) Efficacy and safety of botulinum toxin in adults with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 75(3):459\u2013467","DOI":"10.1002\/art.42342"},{"issue":"1","key":"7237_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/1573397117666211012105611","volume":"18","author":"SM Seyedmardani","year":"2021","unstructured":"Seyedmardani SM, Aghdashi MA, Soltani S, Zonouz GK (2021) Evaluation of botulinum toxin type A and its potential effect on exacerbated Raynaud\u2019s phenomenon in hospitalized scleroderma patients. Curr Rheumatol Rev 18(1):48\u201357","journal-title":"Curr Rheumatol Rev"},{"issue":"1","key":"7237_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10067-021-05900-7","volume":"41","author":"S Shenavandeh","year":"2022","unstructured":"Shenavandeh S, Sepaskhah M, Dehghani S, Nazarinia M (2022) A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis. Clin Rheumatol 41(1):95\u2013104","journal-title":"Clin Rheumatol"},{"issue":"8","key":"7237_CR31","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/1753193413516242","volume":"39","author":"L Uppal","year":"2014","unstructured":"Uppal L, Dhaliwal K, Butler PE (2014) A prospective study of the use of botulinum toxin injections in the treatment of Raynaud\u2019s syndrome associated with scleroderma. J Hand Surg Eur 39(8):876\u2013880","journal-title":"J Hand Surg Eur"},{"issue":"1","key":"7237_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/01.prs.0000244860.00674.57","volume":"119","author":"AL Van Beek","year":"2007","unstructured":"Van Beek AL, Lim PK, Gear AJL, Pritzker MR (2007) Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg 119(1):217\u2013226","journal-title":"Plast Reconstr Surg"},{"issue":"5","key":"7237_CR33","first-page":"e8235","volume":"12","author":"AR Winter","year":"2020","unstructured":"Winter AR, Camargo Macias K, Kim S, Sami N, Weinstein D (2020) The effect of abobotulinum toxin A on the symptoms of Raynaud\u2019s phenomenon: a case series. Cureus 12(5):e8235","journal-title":"Cureus"},{"issue":"7","key":"7237_CR34","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s10072-015-2084-6","volume":"36","author":"X Zhang","year":"2015","unstructured":"Zhang X, Hu Y, Nie Z, Song Y, Pan Y, Liu Y et al (2015) Treatment of Raynaud\u2019s phenomenon with botulinum toxin type A. Neurol Sci 36(7):1225\u20131231","journal-title":"Neurol Sci"},{"issue":"3","key":"7237_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/ajd.12326","volume":"56","author":"H Zhao","year":"2015","unstructured":"Zhao H, Lian Y (2015) Clinical and image improvement of Raynaud\u2019s phenomenon after botulinum toxin type A treatment. Australas J Dermatol 56(3):202\u2013205","journal-title":"Australas J Dermatol"},{"issue":"5","key":"7237_CR36","first-page":"1038","volume":"87","author":"DE Beaton","year":"2005","unstructured":"Beaton DE, Wright JG, Katz JN (2005) Development of the QuickDASH: comparison of three item-reduction approaches. J Bone Joint Surg Am 87(5):1038\u20131046","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"7237_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/2397198318823951","volume":"4","author":"A Fern\u00e1ndez-Codina","year":"2019","unstructured":"Fern\u00e1ndez-Codina A, Ca\u00f1as-Ruano E, Pope JE (2019) Management of Raynaud\u2019s phenomenon in systemic sclerosis\u2014a practical approach. J Scleroderma Relat Disord 4(2):102\u2013110","journal-title":"J Scleroderma Relat Disord"},{"issue":"6","key":"7237_CR38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/reum.2022.120757","volume":"60","author":"MH Jokar","year":"2022","unstructured":"Jokar MH, Baghbani B, Geraylow KR, Shariati J, Mehrad-Majd H, Mirfeizi Z et al (2022) Efficacy of botulinum toxin type A injection for Raynaud\u2019s phenomenon and digital ulcers in patients with systemic sclerosis. Reumatologia 60(6):392\u2013398","journal-title":"Reumatologia"},{"issue":"12","key":"7237_CR39","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.jhsa.2010.09.019","volume":"35","author":"MW Neumeister","year":"2010","unstructured":"Neumeister MW (2010) Botulinum toxin type A in the treatment of Raynaud\u2019s phenomenon. J Hand Surg Am 35(12):2085\u20132092","journal-title":"J Hand Surg Am"},{"issue":"4","key":"7237_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2310\/7750.2008.07044","volume":"12","author":"I Kossintseva","year":"2008","unstructured":"Kossintseva I, Barankin B (2008) Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. J Cutan Med Surg 12(4):189\u2013193","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"7237_CR41","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/archdermatol.2011.1144","volume":"148","author":"L Smith","year":"2012","unstructured":"Smith L, Polsky D, Franks AGJ (2012) Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol 148(4):426\u2013428","journal-title":"Arch Dermatol"},{"issue":"2","key":"7237_CR42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jpurol.2013.10.011","volume":"10","author":"V Figueroa","year":"2014","unstructured":"Figueroa V, Romao R, Salle JLP, Koyle MA, Braga LHP, B\u00e4gli DJ et al (2014) Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures. J Pediatr Urol 10(2):368\u2013373","journal-title":"J Pediatr Urol"},{"issue":"2","key":"7237_CR43","first-page":"151","volume":"18","author":"Z Mackiewicz","year":"1977","unstructured":"Mackiewicz Z, Piskorz A (1977) Raynaud\u2019s phenomenon following long term repeated action of great differences of temperature. J Cardiovasc Surg 18(2):151\u20134","journal-title":"J Cardiovasc Surg"},{"issue":"1","key":"7237_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/PRS.0b013e3181a80576","volume":"124","author":"MW Neumeister","year":"2009","unstructured":"Neumeister MW, Chambers CB, Herron MS, Webb K, Wietfeldt J, Gillespie JN et al (2009) Botox therapy for ischemic digits. Plast Reconstr Surg 124(1):191\u2013201","journal-title":"Plast Reconstr Surg"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07237-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07237-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07237-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T14:02:29Z","timestamp":1736776949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07237-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7237"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07237-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}